Loading

AUTHOR INFO

Beate Wulff

F. Hoffmann-La Roche Ltd


Articles List
Perspective Open Access

Measurable residual disease as a surrogate endpoint for overall survival in acute myeloid leukemia: a call to action

Thomas Prebet , Thomas J. Prior , Reshma Patel , Neerav Monga , Marie-Helene Blanchet Zumofen , Kathryn Matt , Daniel Lopes de Menezes , Carole Longson , Brenda Chyla , Bourras-Rezki Bengoudifa , Beate Wulff , Vicky Huang

The standardization and implementation of new endpoints are crucial for the development of novel therapeutic agents. These endpoints help streamline clinical development while maintaining high standards of care for innovative treatments, ultimately leading to improved patient outcomes. 

Clin Res Oncol, 2026, Volume 2, Issue 1, p1-11 | DOI: 10.46439/Oncology.2.009
Co Authors
Thomas Prebet Bristol Myers Squibb, Bristol Myers Squibb View Profile
Thomas J. Prior Johnson and Johnson, Johnson and Johnson View Profile
Reshma Patel Johnson and Johnson, Johnson and Johnson View Profile
Neerav Monga Johnson and Johnson, Johnson and Johnson View Profile
Marie-Helene Blanchet Zumofen F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd View Profile
Kathryn Matt Johnson and Johnson, Johnson and Johnson View Profile
Daniel Lopes de Menezes Bristol Myers Squibb, Bristol Myers Squibb View Profile
Carole Longson Prof., Independent Senior Adviser, Life Science Policy, HTA and Market Access, Prof., Independent Senior Adviser, Life Science Policy, HTA and Market Access View Profile
Brenda Chyla AbbVie, AbbVie View Profile
Bourras-Rezki Bengoudifa Bristol Myers Squibb, Bristol Myers Squibb View Profile
Vicky Huang Bristol Myers Squibb, Bristol Myers Squibb View Profile